Summary
This 8-K filing from Schering-Plough (related to Merck & Co. due to a joint venture) primarily focuses on two key events. First, it reports on a credit rating downgrade by Standard & Poor's, which was initially placed "On Watch Negative." While S&P lowered the ratings, the filing clarifies that this action does not trigger any specific financial covenants in certain cash flow management arrangements between U.S. and non-U.S. subsidiaries. Investors should note that this downgrade, while not immediately impacting these specific agreements, could have broader implications for the company's borrowing costs and financial flexibility. Second, the filing provides an update on the regulatory progress of a potential new cholesterol-lowering drug. The Merck/Schering-Plough Pharmaceuticals joint venture submitted a New Drug Application (NDA) for an ezetimibe/simvastatin tablet to the FDA in September 2003, and the FDA accepted this filing in November. This indicates the drug is moving through the approval process, which is a positive development for future revenue streams and highlights the importance of this joint venture for both parent companies.
Key Highlights
- 1Schering-Plough's credit ratings were lowered by Standard & Poor's, moving them "Off Watch Negative."
- 2The credit rating downgrade does not trigger specific provisions in two key cash flow management arrangements between U.S. and non-U.S. subsidiaries.
- 3Investors are directed to the Q3 2003 10-Q for details on the "Credit Ratings Triggers" within liquidity discussions.
- 4Merck/Schering-Plough Pharmaceuticals submitted a New Drug Application (NDA) for an ezetimibe/simvastatin tablet to the FDA.
- 5The FDA accepted the NDA filing for the investigational cholesterol-lowering medicine.
- 6The ezetimibe/simvastatin tablet is being developed to reduce elevated cholesterol levels.